Lycia Therapeutics (LYCA Proposed), a Phase 1 biotech targeting allergies and Graves’ disease, set the terms for its $250 million IPO early today – Tuesday, Oct. 20, 2026. The company is offering 14.7 million shares at a price range of $16.00 to $18.00 to raise $249.9 million, if priced at the $17.00 mid-point. This is […]
October 20, 2026 Read MoreThe IPO market is playing the waiting game. IPO investors are anticipating Anthropic’s blockbuster filing – possibly by the end of the week. The IPO Calendar shows no large IPOs on tap for the week of Oct. 19, 2026. (This is the 39th anniversary of Black Monday.) Two small deals may get priced this week. […]
October 19, 2026 Read MoreJump shot: TCGX Acquisition Corp. II (TCXB) – a stock-only SPAC – opened at $11.20 – up 12 percent for a gain of $1.20 from its $10.00 price – in its NASDAQ debut today – Friday, Oct. 16, 2026. TCGX Acquisition II priced its SPAC IPO last night – on Thursday night, Oct. 15, 2026 […]
October 16, 2026 Read MoreCity Therapeutics (CTY), a Phase 1 biotech, upsized its IPO at pricing to 11.11 million shares – up from 9.72 million shares in the prospectus – and priced the deal at $18.00 – the mid-point of its range – to raise $199.98 million on Thursday night, Oct. 15, 2026. Shares of City Therapeutics (CTY) popped […]
October 15, 2026 Read MoreIambic Therapeutics(IAM) priced its IPO at $16.00 – the mid-point – and sold 9.38 million shares – the number in the prospectus – to raise $150 million on Wednesday night, Oct. 14. The Phase I cancer biotech’s stock edged higher in its NASDAQ debut – opening at $16.15 shortly after noon EDT on Thursday, Oct. […]
October 14, 2026 Read MoreIambic Therapeutics (IAM Proposed) and City Therapeutics (CTY Proposed) are in the spotlight this week as the only two deals on the IPO Calendar so far. Both biotechs are set to go public in a year that’s seen a resurgence in the volume of biotech sector IPOs, compared with 2025. This week’s light IPO Calendar […]
October 12, 2026 Read MoreCity Therapeutics (CTY Proposed) unveiled its IPO’s terms early today – 9.72 million shares at a price range of $17.00 to $19.00 to raise $174.96 million, if priced at the $18.00 mid-point of its range, according to its S-1/A filing dated Oct. 9, 2026. This is a NASDAQ listing. (Please see our IPO Calendar for […]
October 9, 2026 Read MoreTRex Bio (TRXB) priced its IPO at $14.00 – the low end of its range – and sold 8.33 million shares – the number in the prospectus – to raise $116.62 million on Thursday night, Oct. 8, 2026. Today –TRex Bio’s stock slipped 50 cents to open at $13.50 – in its NASDAQ debut at […]
Read MoreIambic Therapeutics (IAM Proposed), a biotech targeting breast cancer and lung cancer, unveiled the terms for its $150 million IPO early today and launched the deal for pricing next week. The company is offering 9.38 million shares at a price range of $15.00 to $17.00 to raise $150 million, if priced at the $16.00 mid-point […]
October 8, 2026 Read MoreTRex Bio (TRXB Proposed), an Eli Lilly-backed biotech, unveiled the terms for its $125 million IPO early today: 8.33 million shares at a price range of $14.00 to $16.00 to raise $124.95 million, if priced at the $15.00 mid-point of its range, according to its S-1 filing dated Oct. 5, 2026. This is a NASDAQ […]
October 5, 2026 Read More